Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxi...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Marcellusi, Chiara Bini, Barbara Muzii, Samira Soudani, Alexia Kieffer, Matthieu Beuvelet, Elena Bozzola, Fabio Midulla, Eugenio Baraldi, Paolo Bonanni, Sara Boccalini, Luigi Orfeo
Format: Article
Language:English
Published: AboutScience Srl 2025-01-01
Series:Global & Regional Health Technology Assessment
Subjects:
Cost of Illness
Prevention strategy
Respiratory syncytial virus
Universal immunization
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3182
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/3182

Similar Items